| Line | All comers | HR-positive |
|---|
| Screening, prevention and diagnosis | 1 | · |
| Advanced, first line | 1 | · |
| Second line | 1 | · |
| Other settings | 1 | 1 |
Screening, prevention and diagnosis
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | First line | Vinblastine and prednisone induction for six to twelve weeks, then continuation to twelve months in total (LCH-III); mercaptopurine added for risk-organ disease in some protocols. | | Histiocyte Society evaluation and treatment guidelines; NCI PDQ | 99 |
Second line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Non-response at week six or risk-organ progression | Switch to cytarabine or cladribine; intensive cladribine-cytarabine for refractory risk-organ disease; BRAF inhibitor (vemurafenib, dabrafenib) for BRAF V600E-mutant disease; reduced-intensity allogeneic transplantation in selected cases. | | Histiocyte Society evaluation and treatment guidelines; NCI PDQ | 92 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.